Document Classification

Section Type: RESULTS

Text: At week 52, further reductions with insulin titration resulted in changes from baseline in HbA1c of -0. 81 0. 08 % (-8. 9 0. 9 mmol/mol), -1. 18 0. 08 % (-12. 9 0. 9 mmol/mol), and -1. 27 0. 08 % (-13. 9 0. 9 mmol/mol) with placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively, and final HbA1c of 7. 5 % (58 mmol/mol), 7. 2 % (55 mmol/mol), and 7. 1 % (54 mmol/mol), respectively.